Fillit

Filippo Berio announces exclusive partnership with Alzheimer's Drug Discovery Foundation, supporting critical research and brain health

Retrieved on: 
星期一, 四月 8, 2024
Olive, Fillit, American Museum, Olive oil, Health, Diet, Brain, Cardiovascular disease, Cauchy stress tensor, Natural history, Polyphenol, Antioxidant, Entrepreneurship, Entomology, Partnership, Risk, Inflammation, Ageing, Research, Traffic barrier, MD, Marketing, Cancer, Filippo Berio, Dementia, Drug discovery

LYNDHURST, N.J., April 8, 2024 /PRNewswire/ -- Filippo Berio, one of the nation's top-selling and longstanding olive oil brands, has established an exclusive partnership with the Alzheimer's Drug Discovery Foundation to raise awareness for Alzheimer's disease and contribute crucial funds to support groundbreaking research aimed at finding a cure for Alzheimer's and related dementias. The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health. The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.

Key Points: 
  • The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health.
  • The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.
  • Studies indicate that consuming olive oil may have protective effects on the brain and reduce the risk of Alzheimer's."
  • This will be the second consecutive year Filippo Berio is supporting one of the ADDF's signature fundraising events.

Alzheimer's Drug Discovery Foundation (ADDF) Statement on FDA Decision to Convene Advisory Committee for Donanemab

Retrieved on: 
星期五, 三月 8, 2024
Fillit, Diagnosis, Research, Peripheral, MD, Pathology, Inflammation, FDA, News, Ageing, Drug development, Entrepreneurship, Biomarker, Lilly, Tau, Medicine, Patient, Disease, Donanemab, Biology, Plasma protein binding, Pharmaceutical industry

NEW YORK , March 8, 2024 /PRNewswire/ -- Drugmaker Eli Lilly & Company today announced the FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to further review and discuss donanemab's efficacy and safety profile before making its final decision on whether to grant the drug approval. The advisory committee is scheduled to take place later this year.

Key Points: 
  • The FDA plans to hold an advisory committee to glean more information on the TRAILBLAZER-ALZ 2 trial data and safety profile.
  • The advisory committee is scheduled to take place later this year.
  • "Today's FDA decision is not a setback, but another step forward in the drug approval process, with the regulatory agency doing its due diligence before the distribution of the drug to patients," says Howard Fillit, MD, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF).
  • "The decision to hold an advisory committee before granting approval follows the regulatory process that was used for the other drugs in this class, including Leqembi."

Combination Therapy and Precision Medicine Spotlighted as the Gold Standard for the Next Generation of Alzheimer's Treatments in the Journal of Prevention of Alzheimer's Disease (JPAD)

Retrieved on: 
星期二, 一月 16, 2024
Fillit, Entrepreneurship, Drug, School, Patient, Biology, Risk, Reno 1868 FC, Science, Research, MD, Oxidative stress, Next Generation, Biomarker, Drug development, Internal medicine, University, Geriatrics, Cancer, Ageing, Neuroprotection, UNLV, Journal, Karolinska Institute, Doctor of Science, Medicine, Autophagy, Therapy, Doctor of Philosophy, Syndrome, IHU, Dementia, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a comprehensive issue, "The Biology of Aging: Leading The Next Generation of Alzheimer's Drug Development With a Geroscience Focus," which supports the consensus that combination therapy and precision medicine are the future of Alzheimer's treatment. This landmark publication arrives at a critical time in the Alzheimer's research field following significant drug breakthroughs of anti-amyloid therapies and the emergence of the biology of aging as the leading approach for drug development. This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.

Key Points: 
  • This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.
  • Each of these novel targets introduces a new and much-needed multi-pronged approach for developing Alzheimer's treatments, which can complement anti-amyloid drugs on the market.
  • The development of future therapies will enhance our growing understanding of the disease and how the various pathways interact to affect the disease state."
  • "This is a noteworthy achievement, as the publication will serve as the first extensive roadmap of non-amyloid pathways with the potential to address the complexity of Alzheimer's disease."

StartUp Health Launches Global Alzheimer's Moonshot with Support from the Alzheimer's Drug Discovery Foundation (ADDF) and Gates Ventures

Retrieved on: 
星期一, 一月 8, 2024
Fillit, Moon, Entrepreneurship, Conference, Partnership, Learning, Gates Ventures, Research, Eli Lilly, Human, Fellow, MD, SAN, Dual-energy X-ray absorptiometry, Medicine, Biomarker, Growth, Patient, Diagnosis, History, Dementia, Therapy, Pharmaceutical industry

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot. This initiative aims to break down silos and foster meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. The Alzheimer's Moonshot is an invitation to Health Transformers, Alzheimer's funders, foundations, advocates, and innovators, as well as leading startups and research teams, to unite in pioneering comprehensive, collaborative approaches to Alzheimer's disease.

Key Points: 
  • SAN FRANCISCO, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the 42nd Annual J.P. Morgan Healthcare Conference week, StartUp Health , in partnership with the Alzheimer's Drug Discovery Foundation 's (ADDF) Diagnostics Accelerator (DxA), and Gates Ventures, the private office of Bill Gates, announced the launch of the Alzheimer's Moonshot.
  • "The ADDF welcomes the opportunity to partner with StartUp Health to launch the Alzheimer's Moonshot," notes Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF.
  • Are you an academic founder, founder, startup or research team focused on Alzheimer's innovation who would like to join the Alzheimer's Moonshot?
  • To explore how your organization can become part of the Alzheimer's Moonshot (or one of our 14 global health moonshots) please reach out to us at [email protected] .

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Retrieved on: 
星期四, 十月 26, 2023
Fillit, Plasma, AD, Astrocyte, HD, MD, Conference, Brain, Dementia, Inflammation, Clinical trial, Encephalitis, Disease, Glial fibrillary acidic protein, Risk, Antibody, GFAP, Blood, Patient, Pharmaceutical industry, Medical imaging

The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.

Key Points: 
  • The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.
  • Astrocytes are key regulatory cells in the brain that, under conditions of brain injury or disease, switch from their normal supportive physiological functions to inflammatory activity that is believed to aggravate damage to brain tissue.
  • A committee convened by the Alzheimer’s Association has recently recommended GFAP as a leading blood-based biomarker of astrocytic activation and brain inflammation in AD.
  • Given the many physiological parallels between neurodegenerative processes in HD and AD, we believe that similar biological effects of pepinemab treatment are likely in the two indications.

Alzheimer’s Leaders Discuss How to Shift Science into Clinical Practice During National Alzheimer’s Summit

Retrieved on: 
星期五, 十月 20, 2023
Fillit, Science, FDA, Policy, Food, Heart, Medicare, Government, Climate Change Act 2008, Doctor of Philosophy, Deficit spending, Entrepreneurship, Health, PET, Summit, Clinical trial, Health equity, Ecosystem, Doctor of Science, Centers for Medicare & Medicaid Services, Patient, Diagnosis, CMS, Vanderbilt University Medical Center, John Douglas, Pharmaceutical industry, Vaccine, MD, MSCI

Washington, DC, Oct. 20, 2023 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s this week hosted the 2023 National Alzheimer’s Summit , a groundbreaking event dedicated to applying recent scientific and policy breakthroughs to real-world clinical practice.

Key Points: 
  • Washington, DC, Oct. 20, 2023 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s this week hosted the 2023 National Alzheimer’s Summit , a groundbreaking event dedicated to applying recent scientific and policy breakthroughs to real-world clinical practice.
  • This virtual summit brought together leading healthcare professionals, researchers, policymakers, and advocates on October 17 and 18.
  • “It’s time to shift science into practice.
  • What does that mean?” asked George Vradenburg, Chair and Co-founder of UsAgainstAlzheimer’s at the start of the Summit.

Alzheimer's Drug Discovery Foundation (ADDF) Announces Launch of SpeechDx, the First Study to Generate a Voice Database Paired with Clinical Data for Early Detection of Alzheimer's Disease

Retrieved on: 
星期一, 十月 23, 2023
Fillit, Intelligence, Speech, Alzheimer's Drug Discovery Foundation, Neuroimaging, Biomarker, Gates Ventures, Human, Data, MD, Health, Doctor of Philosophy, Entrepreneurship, Dementia, Research, Tablet, BBRC, Disease, Ace, Machine learning, Emory University, Boston University, Brain, Algorithm, Language, Collection, Diagnosis, Dual-energy X-ray absorptiometry, Pharmaceutical industry, Medical imaging, Mobile phone, Alzheimer's disease

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.

Key Points: 
  • SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms.
  • Study participants will be given handheld tablets with the pre-installed SpeechDx app to capture their voice data.
  • The use of this warehouse of data will be fundamental for the development of new and renewable digital voice biomarkers.
  • Additionally, each participant's voice recording will be paired with clinical data and harmonized across all sites.

Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
星期二, 十月 17, 2023
Fillit, Momentum, Drug development, Amyloid, ET, Ageing, Alzheimer's Drug Discovery Foundation, Drug, Therapy, Doctor of Philosophy, Entrepreneurship, Inflammation, Research, Emerging, Boston Park Plaza, Plasma, Denali, Medicine, Biology, Brain, Cancer, Path, Fujirebio, Alzheimer's Research UK, Pharmaceutical industry, Medical imaging, Medical device, Alzheimer's disease, MD, Disease

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.

Key Points: 
  • This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's.
  • This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau.
  • The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
  • The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics.

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease

Retrieved on: 
星期一, 十月 9, 2023
Research, Seniors, Neurology, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Fillit, Doctor of Philosophy, Brain, Caregiver, Therapy, Memory, Neurodegenerative disease, Alzheimer's disease, Learning, Patient, Pharmaceutical industry, MD

CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.

Key Points: 
  • CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.
  • “We are thrilled to receive this investment from the Alzheimer’s Drug Discovery Foundation which will be used to advance CST-3056, our proprietary α1A-AR agonist program, from preclinical development to completion of Phase 1 studies,” said Anthony Ford, PhD, chief executive officer, CuraSen Therapeutics.
  • “Coupled with our two other Phase 2 clinical-stage programs in neurodegenerative diseases, CST-2032 and CST-103, CuraSen is well-positioned to deliver critically needed neurodegenerative disease treatment options to the millions of patients and caregivers in need.”
    “Alpha-1A adrenoceptors are known to help regulate neurotransmission and are prevalent in the areas of the brain important to memory and learning, making them a promising target for Alzheimer’s drug development by offering potential neuroprotective benefits,” said Howard Fillit, MD, co-founder and chief science officer, Alzheimer’s Drug Discovery Foundation.
  • “Novel approaches, such as the one CuraSen is pursuing, are critical as we develop the next class of Alzheimer’s therapeutics that will move us closer to treating Alzheimer's through combination therapy and precision medicine.”
    CuraSen will commence non-clinical studies early in 2024 and expects to initiate Phase 1 clinical testing later that year.

Revolutionizing Alzheimer's Prevention and Treatment: The Alzheimer's Drug Discovery Foundation and the FINGERS Brain Health Institute Announce Precision Prevention Partnership

Retrieved on: 
星期三, 十月 4, 2023
Fillit, Karolinska Institute, Medicine, Partnership, Drug development, Therapy, Senior, Prevalence, Diabetes, AARP, Alzheimer's Drug Discovery Foundation, Health, Cancer, Ageing, Brain, Risk, Biomarker, Inflammation, Doctor of Philosophy, Dementia, Organization, Incidence, Science, Physician, Patient, Drug discovery, Biology, Metformin, Gates Ventures, Entrepreneurship, FDA, Geriatrics, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease, MD, Policy

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) announced today a new Precision Prevention Partnership, a unique collaboration set to transform the landscape of Alzheimer's disease prevention and treatment. Together, the ADDF and the FBHI will advance physicians' ability to tailor precision prevention approaches that combine lifestyle interventions and therapeutics to help delay or prevent the onset of the disease based on patients' individual risk and biomarker profiles.

Key Points: 
  • Alzheimer's is a complex disease, and a one size fits all approach will not effectively treat its varied causes and forms."
  • "With this new collaboration, our two organizations will redefine the prevention landscape by targeting several risk factors simultaneously to get optimal preventive effects against Alzheimer's disease."
  • This model will serve as a template for the next generation of combination clinical trials, helping to speed up the drug development pipeline.
  • Accelerating the development of new biomarkers for aging, helping improve Alzheimer's diagnostics and aiding in the development of novel drugs.